144 - January 14, 2026 | SEC Filings

Brief

This Form 144 discloses director Merline A. Saintil's intent to sell 12,500 common shares acquired via RSUs in 2023, valued at $1,082,250. She sold 35,000 shares totaling ~$2.05M in Dec 2025 under a 10b5-1 plan adopted Sep 17, 2025. Relevant to investors as routine insider selling with certification of no undisclosed adverse info.

Detailed Brief

Form 144 is filed by Rocket Lab director Merline A. Saintil notifying of proposed sale of 12,500 common shares on or about January 14, 2026, through broker Morgan Stanley, with aggregate market value $1,082,250 based on 534M shares outstanding. Shares originate from restricted stock units granted by issuer on August 22, 2023. In the past three months, Saintil sold 35,000 shares across four transactions in December 2025: 10k on 12/4 ($480k), 15k on 12/12 ($975k), 5k on 12/17 ($272k), and 5k on 12/19 ($325k), two under 10b5-1. The sale relies on Rule 10b5-1 plan from September 17, 2025. Saintil certifies no knowledge of undisclosed material adverse information about Rocket Lab's operations. This is standard for insiders selling vested equity in a public company like Rocket Lab, a space launch provider.

Key Telemetry

• Director Merline Saintil to sell 12,500 common shares (~$1.08M) on 1/14/2026 via Morgan Stanley.

• Shares from 8/22/2023 RSU grant; under 10b5-1 plan adopted 9/17/2025.

• Past 3 months: Sold 35,000 shares for ~$2.05M in Dec 2025.

• Certifies no undisclosed material adverse information.

• Negligible vs. 534M shares outstanding.

Impact Vector

Routine insider sale under pre-established 10b5-1 plan signals no immediate concerns, as Saintil affirms no hidden adverse info. The 12,500 shares (plus recent 35k) represent minor dilution (<0.01% of outstanding), unlikely to impact stock price significantly. Strategic irrelevance to Rocket Lab's launch business; monitor aggregate insider selling trends or volume spikes for sentiment signals.